Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial

Publikation: Bidrag til tidsskriftLetterForskningfagfællebedømt

  • Jens Christian Laursen
  • Viktor Rotbain Curovic
  • Marjolein Y.A.M. Kroonen
  • Niels Jongs
  • Emilie H. Zobel
  • Tine W. Hansen
  • Marie Frimodt-Møller
  • Gozewijn D. Laverman
  • Adriaan Kooy
  • Frederik Persson
  • Hiddo J.L. Heerspink
  • Christian Stevns Hansen
  • Rossing, Peter
TidsskriftDiabetes, Obesity and Metabolism
Udgave nummer10
Sider (fra-til)3064-3067
Antal sider4
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
The authors thank all participants and clinical trial staff for participation in this study. The study was funded by Boehringer Ingelheim and a grant from the Novo Nordisk Foundation (NNF14OC0013659 PROTON Personalizing Treatment of Diabetic Nephropathy). The funders were not involved in the design, execution, analysis, interpretation of the data nor in the writing of the manuscript.

ID: 365814070